ZyVersa Therapeutics, Inc. ZVSA
0.10
0.00
0.00%
as of 24 Sep
- Market cap
- $970.0K
- P/E
- 0.0×
Follow ZVSA
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
0.05 | 0.04 | 0.08 | 0.04 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.23 | 0.18 | 0.03 | 0.04 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.45 | 0.61 | 0.07 | 0.69 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.95 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.10) | (0.07) | (0.18) | (0.32) | |
Cash per Share |
0.04 | 0.02 | 0.07 | 0.02 | |
Shareholders Equity per Share |
(1.74) | (2.08) | (1.51) | 1.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.74) | (2.08) | (1.51) | 1.27 | |
Free Cash Flow |
(0.80) | (0.41) | (1.41) | (1.52) | |
Working Capital |
(14.12) | (12.39) | (11.77) | (12.14) | |
Net Current Asset Value |
(14.12) | (12.39) | (11.77) | (12.99) | |
| Other line items | |||||
Quick Ratio |
0.02 | 0.01 | 0.04 | 0.01 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.10) | (0.07) | (0.18) | (0.32) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
9.92 | 9.73 | 9.54 | 9.05 | |
Average Assets |
10.86 | 10.53 | 10.23 | 19.56 | |
Average Common Equity |
(3.00) | (1.94) | (2.35) | 7.36 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates